<em>Plasmodium vivax</em> and Drug Resistance
Resistance to antimalarial drugs is a threat to global efforts to eliminate malaria by 2030. Currently, treatment for vivax malaria uses chloroquine or ACT for uncomplicated P. vivax whereas primaquine is given to eliminate latent liver stage infections (a method known as radical cure). Studies on P...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2021
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/76742 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: <em>Plasmodium vivax</em> and Drug Resistance
- <em>Plasmodium vivax</em> and <em>Plasmodium ovale</em> in the Malaria Elimination Agenda in Africa
- Elimination of <em>Plasmodium vivax</em> Malaria: Problems and Solutions
- Circumsporozoite Protein from <em>Plasmodium vivax</em> and Its Relationship to Human Malaria
- Molecular Dynamics of Mosquito-<em>Plasmodium vivax</em> Interaction: A Smart Strategy of Parasitism
- Plasmodium Species and Drug Resistance
- Gametocitos de Plasmodium vivax y Plasmodium falciparum : etapas relegadas en el desarrollo de vacunas /